EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced that data from a 17-question survey sponsored by the Company was published in a poster entitled, “Improving Patient Acceptability and Adherence in Psoriasis Treatment,” at the 42nd Annual Fall Clinical Dermatology Conference® taking place October 20-23, 2022, in Las Vegas, NV.
Related news for (NOVN)
- FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
- Novan to Present at the Virtual Investor 2023 Companies to Watch Event
- Novan to Present at the Virtual Investor 2023 Companies to Watch Event
- Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
- Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum